Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $138.00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target raised by stock analysts at BMO Capital Markets from $129.00 to $138.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ price target would suggest a potential downside of 1.93% from […]

Related Keywords

United States ,Neurocrine Biosciences ,Davidw Boyer ,Eric Benevich ,Wells Fargo Company ,Quadrant Capital Group ,Sunbelt Securities Inc ,Neurocrine Biosciences Inc ,Jpmorgan Chase Co ,First Horizon Advisors Inc ,Envestnet Portfolio Solutions Inc ,Barclays ,Needham Company ,Securities Exchange Commission ,Commonwealth Equity Services ,Get Free Report ,Wells Fargo ,Exchange Commission ,Horizon Advisors ,Capital Group ,Portfolio Solutions ,Equity Services ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Bmo Capital Markets ,